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Objective: Accumulating evidence for differential expression of microRNA-224 (miR-224) in various types of human
cancer suggests that it may be play a crucial role in tumor biology. The previous microarray detection also shown
that miR-224 was one of miRNAs with significant upregulation in cervical cancer tissues relative to adjacent normal
tissues. However, little is known about the function of miR-224 in human cervical cancer. The aim of this study was
to investigate the clinical significance of miR-224 expression in cervical cancer.
Methods: MiR-224 expression in 126 pairs of fresh human cervical cancer and adjacent normal tissues was
measured by real-time quantitative RT-PCR assay.
Results: miR-224 expression was significantly upregulated in cervical cancer tissues when compared with
corresponding adjacent normal tissues (P < 0.001). It was also significantly higher in the cancerous tissues of
patients with advanced FIGO stage cervical cancer than those with early FIGO stage (P = 0.02). In addition, miR-224
was expressed at significantly higher levels in lymph node metastasis-positive patients than in lymph node
metastasis-negative patients (P = 0.008). Moreover, we found that lesser differentiated tumors expressed higher
miR-224 (P = 0.03). Finally, there were sufficient evidence to confirm its value in the status of vascular invasion
(P = 0.01) and human papillomavirus (HPV) infection (P = 0.02) in cervical cancer. More importantly, Kaplan-Meier
analysis showed that cervical cancer patients with high miR-224 expression tend to have shorter overall survival. In
multivariate analysis stratified for known prognostic variables, miR-224 was identified as an independent prognostic
marker.
Conclusion: Our data indicated that miR-224 upregulation was associated with aggressive progression and poor
prognosis in cervical cancer. MiR-224 was identified for the first time as an independent marker for predicting the
clinical outcome of cervical cancer patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
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Cervical cancer is the third most common malignancy
among women worldwide, with an estimated global inci-
dence of over 500,000 new cases and tremendously high
death cases of 260,000 annually [1]. It is the result of a
multistep process that involves the transformation of
normal cervical epithelium to preneoplastic cervical
intraepithelial neoplasia that is subsequently transformed
to invasive cervical cancer [2]. Early detection and diag-
nosis have become accurate and inexpensive through
routine papanicolaou tests, and the recent advent of
human papillomavirus (HPV) vaccine may have a signi-
ficant impact on prevention of cervical cancer which is
strongly associated with infection and subsequent trans-
formation of cervical cells by specific HPV subtypes [3].
Although radiotherapy, chemotherapy and surgery have
been recently used as standard treatment modalities for
patients with cervical cancer, with consequent disease
remission, clinical outcomes vary significantly between
patients and can be difficult to predict. Therefore, it is
important to understand the complete knowledge of the
molecular biology, genetics, causes and cellular origin of
cervical cancers which are of value in the development
of improved therapeutic strategies and in the identifica-
tion of prognostic markers.
MicroRNAs (miRNAs) are short non-coding RNAs
that were initially discovered in the early 1990s and gen-
erally control gene expression at the posttranscriptional
level through mRNA degradation and/or translational
repression [4]. miRNAs bind to the 3’ untranslated
regions (3’-UTR) of their target mRNAs, mediating
translational repression and/or mRNA degradation [5].
Thousands of miRNAs have been identified in nema-
todes, insects, birds, amphibians, fishes, plants, mam-
mals, and even viruses using molecular cloning and
bioinformatics prediction strategies [6]. Recent studies
have suggested and reinforced their roles as important
regulators of gene expression in a broad range of phy-
siological and pathological processes, including cancer
development and progression. Aberrant expression
levels of miRNAs have been demonstrated to be in-
volved in several forms of solid tumors such as hepato-
cellular carcinoma, colorectal cancer, prostate cancer,
cervical cancer, breast cancer, ovarian carcinoma, and
lung cancer [7-10]. They function either as tumor sup-
pressors or oncogenes according to the roles of their
target genes. Changes in their expression are able to be
used as robust and important biomarkers for cancer
risk, diagnosis and prognosis, even as miRNA-based
therapeutic targets with a great interest. For example,
several of miRNAs, such as miR-143, miR-145, miR-21,
miR-424 and miR-205 have consistently been reported
as dysregulated in cervical cancer [11-15]. Especially,
Wang et al. [11] found that miR-143 and miR-145 wereunderexpressed in both cervical cancer tissues and HPV-
infected tissues with pre-neoplastic lesions, suggesting
that their reduction take place in an early step before can-
cer development. Xu et al. [13] identified a crucial tumor
suppressive role of miR-424 in the progression of cervical
cancer at least partly via upregulating the expression of
Chk1 and p-Chk1, suggesting that miR-424 may be a can-
didate of prognostic predictor or an anticancer therapeutic
target for cervical cancer patients.
In the previous study of Rao et al. [16], using MicroRNA
array, they detected differential expression of miRNAs in
human cervical cancer tissues relative to adjacent normal
cervical tissues. In cervical cancer tissues, miR-224 was
found to be one of the upregulated miRNAs (2.7221-fold
higher than in adjacent normal cervical tissues). However,
little is known about the function of miR-224 in human
cervical cancer. The aim of this study was to investigate
the clinical significance of miR-224 expression in cervical
cancer.
Materials and methods
Patients and tissue samples
This study was approved by the Research Ethics Com-
mittee of the Third Affiliated Hospital of Inner Mongolia
Medical University and the First Affiliated Hospital of
Inner Mongolia Medical University, P. R. China. Written
informed consent was obtained from all of the patients.
All specimens were handled and made anonymous
according to the ethical and legal standards.
Fresh cervical cancer and matched adjacent normal
tissue specimens were collected from 126 patients who
underwent surgery between May 2003 and August 2007
in the Third Affiliated Hospital of Inner Mongolia Me-
dical University and the First Affiliated Hospital of
Inner Mongolia Medical University. The corresponding
adjacent normal tissues were obtained 3 cm beyond the
boundary of cervical cancer tissues. The fresh tissue
specimens were immediately frozen in liquid nitrogen
until use. No patients had preoperative chemotherapy,
radiotherapy, or other treatment history or other in-
flammatory diseases. The cervical cancer patients were
aged from 26 to 68 years with a median of 50 years.
Pathological diagnosis of all 126 cervical cancer patients
was cervical squamous cell carcinoma. The degree of
differentiation was well differentiated in 45 cases, mod-
erately differentiated in 46 cases, and poorly differenti-
ated in 35 cases. A total of 82 cases had lymph node
metastases, while 44 cases did not have lymph node
metastases. The clinical stage according to the Inter-
national League of Gynecology and Obstetrics (FIGO,
2009) was 28 cases of stage Ib, 36 cases of stage IIa, 32
cases of stage IIb, and 30 cases of stage IIIa. A total of
64 stage Ib~IIa cases were grouped as early stage, and a
total of 62 stage IIb~IIIa cases were grouped as late
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were summarized in Table 1.
Clinical follow-up was available for all patients (median,
51.9 months). Overall survival time was calculated from
the date of the initial surgical operation to death. Patients,
who died of diseases not directly related to their cervical
cancers or due to unexpected events, were excluded from
this study. Follow-up information of all patients was
updated every 3 months for the first 2 years, every
4 months for the third year, every 6 months for the fourth
and fifth years, and then every year thereafter by telephone
visit and questionnaire letters. Death of the participants
was ascertained by reporting from the family and verified
by review of public records.
Real-time quantitative RT-PCR for miRNA
Real-time quantitative RT-PCR for miRNA was per-
formed to detect the expression levels of miR-224 in
human cervical cancer and matched adjacent normal
tissues. Total RNA was extracted from tissue samples of
126 pairs of cervical cancer and adjacent normal tissues
using TRIzol (Invitrogen) according to the manufac-
turer’s protocol. RNU6B was used as internal control.Table 1 Association between miR-224 expression and differen






















(+) 78The specific cDNA of miR-224 and RNU6B were synthe-
sized from total RNA using gene-specific primers
according to the TaqMan MicroRNA assays protocol
(Applied Biosystems, Foster City, CA, USA). Reverse tran-
scriptase reactions contained 10 ng of total RNAs,
50 nmol/l stem-loop RT primer, 1× RT buffer, 0.25 mmol/
l each of deoxynucleotide triphosphate (dNTP), 3.33 U/μl
MultiScribe reverse transcriptase, and 0.25 U/μl RNase
Inhibitor. The 20-μl reaction volumes were incubated in
Bio-Rad i-Cycler (Bio- Rad Laboratories, Hercules, CA,
USA) in a 96-well plate for 30 min at 15°C, 30 min at
40°C, 5 min at 85°C, and then held at 4°C. Real-time PCR
was performed using an Applied Biosystems 7500 real-
time PCR system. The reaction mixture (10 μL total
volume per well) included 2 ng cDNA, 1× TaqMan
Universal PCR master mix, and 1 μl of primers and probe
mix of the TaqMan MicroRNA Assays. Relative quanti-
fication of target miRNA expression was evaluated using
the comparative cycle threshold (CT) method. The raw
data were presented as the relative quantity of target
miRNA, normalized with respect to RNU6B. Each sample
was examined in triplicate. Mean normalized gene expres-
sion ± standard deviation (SD) was calculated from three
independent experiments.t clinicopathological features of human cervical cancers
miR-224 expression P
High (n, %) Low (n, %)
30 (50.0) 30 (50.0) NS
36 (54.5) 30 (45.5)
30 (51.7) 28 (48.3) NS
36 (52.9) 32 (47.1)
4 (14.3) 24 (85.7) 0.03
12 (37.5) 20 (62.5)
50 (75.8) 16 (24.2)
20 (31.3) 44 (68.7) 0.02
46 (74.2) 16 (25.8)
24 (30.4) 55 (69.6) 0.008
42 (89.4) 5 (10.6)
20 (27.8) 52 (72.2) 0.01
46 (85.2) 8 (14.8)
10 (20.8) 38 (79.2) 0.02
56 (71.8) 22 (28.2)
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All computations were carried out using the software of
SPSS version13.0 for Windows (SPSS Inc, IL, USA). Data
were expressed as mean ± SD. The analysis of variance
(ANOVA) was used to determine the statistical differences
among the groups. The Kaplan-Meier method was used to
estimate survival rates, and the log-rank and the Wilcoxon
rank sum tests were used to assess survival differences be-
tween groups. The Cox proportional hazards model for
multivariate survival analysis was used to assess predictors
related to survival. Differences were considered statisti-
cally significant when p was less than 0.05.Results
MiR-224 upregulation in human cervical cancer
MiR-224 expression was detected in 126 pairs of human
cervical cancer and adjacent normal tissues by real-time
quantitative RT-PCR. As shown in Figure 1, after nor-
malization to RNU6B expression levels, the expression
level of miR-224 in cervical cancer tissues (mean ± SD:
5.4 ± 0.9) was significantly higher than that in adjacent
normal tissues (mean ± SD: 3.2 ± 0.9, P < 0.001). The
median expression level of miR-224 (5.4) was used as a
cutoff point to divide all 126 patients into two groups:
cervical cancer patients who express miR-224 at levels
less than the cutoff value were assigned to the low ex-
pression group (mean expression value 4.6, n = 60), and
those with expression above the cutoff value were
assigned to the high expression group (mean expression
value 6.1, n = 66).Figure 1 MiR-224 expression in 126 pairs of cervical cancer
and adjacent normal tissues were respectively detected by
real-time quantitative RT-PCR assay. After normalization to
RNU6B, the expression level of miR-224 in cervical cancer tissues
(mean ± SD: 9.8 ± 0.9) was significantly higher than that in adjacent
normal tissues [mean ± SD: 3.2 ± 0.9, ratio (cervical cancer/normal
controls) =3.1, P < 0.001].MiR-224 upregulation associates with aggressive
clinicopatholigcal parameters of human cervical cancer
Table 1 summarized the association between miR-224
expression and clinicopathological parameters in cervical
cancers. miR-224 expression was significantly higher in
the cancerous tissues of patients with advanced FIGO
stage cervical cancer than those with early FIGO stage
(P = 0.02, Table 1). In addition, miR-224 was expressed
at significantly higher levels in lymph node metastasis-
positive patients than in lymph node metastasis-negative
patients (P = 0.008, Table 1). Moreover, we found that
lesser differentiated tumors expressed higher miR-224
(P = 0.03, Table 1). Finally, there were sufficient evidence
to confirm its value in the status of vascular invasion
(P = 0.01, Table 1) and human papillomavirus (HPV) in-
fection (P = 0.02, Table 1) in cervical cancer.
MiR-224 upregulation associates with poor prognosis in
patients with human cervical cancer
The association between miR-224 expression and survival
of cervical cancer patients was investigated by Kaplan–
Meier analysis and log-rank test. During the follow-up
period, 66 of the 126 patients (52.4%) had died. As shown
in Figure 2, cervical cancer patients with high miR-224
expression tend to have shorter overall survival than those
with low miR-224 expression (log-rank test: P < 0.001).
Univariate analysis demonstrated that FIGO stage (P <
0.001), the status of lymph node metastasis (P = 0.006)
and vascular invasion (P = 0.01), and miR-224 expression
(P < 0.001) were significantly associated with overall sur-
vival of cervical cancer patients (Table 2). No significantFigure 2 Kaplan-Meier curves for survival time in patients with
cervical cancers divided according to miR-224 expression:
significantly shorter survival times for patients with high miR-224
expression than for those with low miR-224 expression (P < 0.001).
Table 2 Univariate and multivariate analysis of prognostic parameters in patients with cervical cancers by Cox
regression analysis
Variables Univariate log-rank test (P) Cox multivariable analysis (P) Relative risk (RR)
Age at diagnosis (years)
<50 vs. ≥50 0.3 0.7 0.6
Tumor size (cm)
<4.0 vs. ≥4.0 0.6 0.8 0.6
FIGO stage
Ib~IIa vs. IIb~IIIa <0.001 0.01 6.2
Histological grades
Well ~ moderately differentiated vs. poor differentiated 0.08 0.10 1.3
Lymph node metastasis
No vs. Yes 0.006 0.02 3.9
Vascular invasion
No vs. Yes 0.01 0.04 2.7
HPV
(−) vs (+) 0.06 0.1 1.1
MiR-224 expression
High vs Low <0.001 0.009 6.8
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histological grade, and HPV status and patient outcome.
Multivariate analysis using the Cox proportional hazards
model for all variables that were significant in the univa-
riate analysis showed that FIGO stage (P = 0.01), the status
of lymph node metastasis (P = 0.02) and vascular invasion
(P = 0.04), and miR-224 expression (P = 0.009) were in-
dependent prognostic factors for patients with cervical
cancer (Table 2).
Discussion
Cervical cancer remains one of the leading causes of cancer
death in women worldwide [17]. In spite of the develop-
ment of advanced therapeutic strategies, the prognosis in
patients with this cancer varies significantly and is hard to
predict. Treatment outcome still depends primarily on
early detection and diagnosis. Recent studies have
demonstrated that some abnormal molecular biology
changes may play central roles in the tumorigenesis and
the development of cervical cancer [18-24]. For example,
Liu et al. [25] reported that genomic amplification of
hTERC gene may be associated with more progressive cer-
vical cancer; Imura et al. [26] demonstrated that Lam-5
was a useful biomarker in the evaluation of invasiveness in
cervical adenocarcinoma. Therefore, it is critical to identify
biomarkers for the early diagnosis and the early identifica-
tion of patients with a high risk of treatment failures, in
order to modify therapeutic methods for improving over-
all survival of patients with cervical cancer.
miR-224 is a family of miRNA precursors found in
mammals, including humans. It was identified and ends
mapped by cloning from Weri cells in human. Thesequence of miR-224 maps to chromosome X [27]. Accu-
mulating evidences for differential expression of miR-224
in various types of human cancer suggest that it may be
play a crucial role in tumor biology. However, it is also
characterized by contradictory properties, since it can pro-
mote or inhibit cancer cell growth, depending on the ma-
lignancy type. For example, miR-224 is one of the most
commonly up-regulated miRNAs in hepatocellular carcin-
oma [28]. Overexpression of miR-224 in liver cells was
reported to increase cell proliferation and apoptosis as well
as cell migration and invasion [29]. Up-regulated miR-224
was also identified in a subtype of medulloblastomas.
Exogenous expression of miR-224 was found to inhibit
proliferation, increase radiation sensitivity and reduce
anchorage-independent growth of medulloblastoma cells
[30]. In breast cancer cell lines, Huang et al. [31] found that
the overexpression of miR-224 which plays an important
role in metastasis of cancer cells to the bone by directly
suppressing the RKIP tumor suppressor. In addition to
these, the upregulation of miR-224 was also shown in ag-
gressive pancreatic ductal adenocarcinoma [32], clear cell
renal cell carcinoma [33], thyroid cancer [34] and bladder
cancer [35]. In contrast, a downregulation of miR-224 has
been observed in ovarian cancer [36], prostate cancer [37]
and oral carcinoma [38].
Observations mentioned above of upregulation or
downregulation of miR-224 in different tumor types
suggest that miR-224 may have different functions in can-
cer development depending on the cell type involved. Pre-
vious study has shown miR-224 to have increased
expression in cervical cancer [16]. For a more comprehen-
sive insight into the clinical value of miR-224, we in the
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assay to explore the expression profile of this miRNA as
well as to investigate its association with clinicopatho-
logical features of cervical cancer patients. Our data proved
that miR-224 expression was significantly higher in cervical
cancer compared with that in adjacent normal tissues. In
addition, miR-224 expression was also proved to be asso-
ciated with histological grade, FIGO stage, HPV status,
lymph node metastasis, and vascular invasion for high
miR-224 expression was more frequently detected in cer-
vical cancer with poor differentiation, advanced FIGO
stage, positive HPV infection, lymph node metastasis, and
vascular invasion, which strongly suggested that miR-224
was involved in the invasion and metastasis of cervical
cancer. More importantly, we proved that miR-224 ex-
pression was significantly associated with overall survival
of patients with cervical cancer. In support of this,
Kaplan-Meier analysis of overall survival showed that
patients with tumors of high miR-224 expression tend to
have a significantly shorter overall survival compared with
patients whose tumors do not, indicating that high miR-
224 expression is a marker of poor prognosis for patients
with cervical cancer. Cox proportional hazards model ad-
justed for known prognostic variables such as histological
grade, FIGO stage, HPV status, lymph node metastasis,
and vascular invasion proved that miR-224 was an inde-
pendent prognostic marker for cervical cancer. Thus,
miR-224 could be used as a molecular prognostic marker
additive to the known prognostic indicator, in order to
identify patients who are more likely to have higher risk of
death, thus, should receive more aggressive treatment.
In conclusion, our data indicated that miR-224 upre-
gulation was associated with aggressive progression and
poor prognosis in cervical cancer. MiR-224 was identified
for the first time as an independent marker for predicting
the clinical outcome of cervical cancer patients.
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